Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Hamartoma Syndrome, Multiple 1Glioblastoma 1Castration-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Diseases 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 170130-nm albumin-bound paclitaxel 54Albumin-Bound Paclitaxel 42Oxaliplatin 33Fluorouracil 32pembrolizumab 30Capecitabine 30Leucovorin 28Irinotecan 28Radiotherapy 25Nivolumab 22Erlotinib Hydrochloride 21Taxes 19Cisplatin 19Bevacizumab 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiosurgery 11Ipilimumab 11Cyclophosphamide 11Drug Therapy 10Carboplatin 10Biopsy 10Paclitaxel 9Docetaxel 9Cetuximab 9trametinib 8olaparib 8durvalumab 8Sorafenib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Neoplasms × dactolisib × Clear all
NCT01337765 2020-10-09

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Pfizer

Phase 1 Completed
29 enrolled
BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡